▶ 調査レポート

結核診断の世界市場:結核検査種類別(放射線透過検査、試験室検査、核酸検査、サイトカイン検出検査、薬剤耐性検査)、エンドユーザー別、地域別分析

• 英文タイトル:Global Tuberculosis Diagnostics Market - Segmented by Diagnostic Test Type, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)
• レポートコード:B-MOR-06009
• 出版社/出版日: / 2018年6月20日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥471,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥499,500 (USD4,500)▷ お問い合わせ
  Corporate User¥971,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、結核診断の世界市場について調べ、結核診断の世界規模、市場動向、市場環境、結核検査種類別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・結核診断の世界市場インサイト
・結核診断の世界市場環境
・結核診断の世界市場動向
・結核診断の世界市場規模
・結核診断の世界市場規模:結核検査種類別
・結核診断の世界市場規模:エンドユーザー別
・結核診断の世界市場:地域別市場規模・分析
・結核診断の北米市場規模・予測
・結核診断のアメリカ市場規模・予測
・結核診断のヨーロッパ市場規模・予測
・結核診断のアジア市場規模・予測
・関連企業情報・競争状況

The global tuberculosis diagnostics market is expected to register a CAGR of nearly 4.5%, during the forecast period of 2018-2023. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies. The rising burden of tuberculosis and technological advancements play a crucial role in the growth of the market studied. Owing to the presence of a large, diversified patient population, rising prevalence of tuberculosis, and increasing healthcare infrastructure with an expanding private sector, Asia-Pacific has captured the largest market share.
Rising Burden of Tuberculosis and Multi-drug Resistant Tuberculosis (MDR TB)

According to the World Health Organization (WHO), about 10 million people are affected by tuberculosis, each year. Further, tuberculosis is the leading cause of death from a single infectious agent, ranking above HIV/AIDS. In addition, the WHO also states that the developing economies of Asia-Pacific, Africa, and Latin America account for the major burden related to tuberculosis, MDR TB, and TB associated with HIV, as of 2017. As per a 2017 report of the WHO, about 153,000 patients with MDR/rifampicin resistant (RR) TB were detected worldwide, in 2016. The developed countries, such as the United States and the United Kingdom are also struggling with the sluggish eradication of TB, as per the Centers for Disease Control and Prevention (CDC). Thus, a large section of the world population is affected with tuberculosis each year, thus boosting the growth of the tuberculosis diagnostics market.
Other factors driving this market are – increasing R&D investments, robust product pipeline, and increasing government initiatives and rising awareness in the emerging economies.

High Cost Associated with Tuberculosis Diagnostics
The cost associated with tuberculosis diagnostics varies across laboratories and hospitals, globally. According to Unitaid, the use of GeneXpert MTB/RIF is primarily hampered owing to its high cost, particularly in the emerging markets. Further, China and India were among the countries that reflect higher costs of tests and increased expansion of the private sector. This is further linked with the unavailability of proper laboratory capacities. In some cases, the diagnostic tools have sub-optimal sensitivity and specificity, which are accompanied by the high costs of reference standard test and mycobacterial culture. Thus, over the forecast period, cost is expected to be one of the major restraining factors for the growth of the market studied.

Asia-Pacific Poised to Dominate the Tuberculosis Diagnostics Market
Owing to the presence of a large, diversified patient population and high burden of tuberculosis, Asia-Pacific is expected to retain its market position, over the forecast period. Countries, such as India, China, Indonesia, and Afghanistan are among the top-priority countries for the control of communicable diseases, according to the WHO. China and India registered the highest number new cases of tuberculosis annually, followed by African and Latin American countries. The emerging economies are witnessing significant growth of the private sector, combined with the public sector, which provides considerable opportunities for the growth of the market studied.

Key Developments in the Market
• Jun 2018 – Qiagen welcomed new guidelines from the American Academy of Pediatrics (AAP) for screening children as young as two years old, for latent tuberculosis infection.
• May 2018 – Oxford Immunotec Global PLC’s T-SPOT.TB test for tuberculosis infection was included in the first edition of the WHO model list of essential in-vitro diagnostics.

Major Players – ABBOTT, BECTON, DICKINSON AND COMPANY, BIOMÉRIEUX SA, CEPHEID, F. HOFFMANN-LA ROCHE AG, HAIN LIFESCIENCE GMBH, HOLOGIC CORPORATION, QIAGEN, SIEMENS, AND THERMO FISHER SCIENTIFIC INC., amongst others.

Reasons to Purchase this Report
• Current and future of tuberculosis diagnostics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• The regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
5.3 Pipeline Analysis
5.4 Regulatory Framework
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Burden of Tuberculosis and Multidrug-resistant Tuberculosis (MDR-TB)
6.1.2 Increasing R&D Investments and Intensive Product Pipelines
6.1.3 Increasing Government Initiatives and Rising Awareness in the Emerging Markets
6.2 Market Restraints
6.2.1 High Costs Associated with Tuberculosis Diagnostics
6.2.2 Low Coverage or Absence of Insurance in the Emerging Markets
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Diagnostic Test Type
7.1.1 Radiographic Test
7.1.2 Laboratory Test
7.1.2.1 Smear Microscopy
7.1.2.2 Culture-based Test
7.1.3 Nucleic Acid Testing
7.1.4 Cytokine Detection Test
7.1.5 Drug Resistance Test
7.1.6 Others
7.2 By End User
7.2.1 Hospital/Clinic
7.2.2 Diagnostics/Research Laboratory
7.2.3 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott
9.2 Becton, Dickinson and Company
9.3 BioMérieux SA
9.4 Cepheid
9.5 F. Hoffmann-La Roche AG
9.6 Hain Lifescience GmbH
9.7 Hologic Corporation
9.8 Qiagen
9.9 Siemens
9.10 Thermo Fisher Scientific Inc.
*List Not Exhaustive
10. Future of the Market